214 related articles for article (PubMed ID: 28636293)
21. Medical therapy of HCC.
Vogel A; Saborowski A
J Hepatol; 2022 Jan; 76(1):208-210. PubMed ID: 34538616
[No Abstract] [Full Text] [Related]
22. Systemic therapies in hepatocellular carcinoma: present and future.
Bertino G; Di Carlo I; Ardiri A; Calvagno GS; Demma S; Malaguarnera G; Bertino N; Malaguarnera M; Toro A; Malaguarnera M
Future Oncol; 2013 Oct; 9(10):1533-48. PubMed ID: 24106903
[TBL] [Abstract][Full Text] [Related]
23. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
24. [Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].
Zhang DZ; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):834-837. PubMed ID: 31941237
[TBL] [Abstract][Full Text] [Related]
25. Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.
Eatrides J; Wang E; Kothari N; Kim R
Cancer Control; 2017; 24(3):1073274817729243. PubMed ID: 28975834
[TBL] [Abstract][Full Text] [Related]
26. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies.
da Motta Girardi D; Correa TS; Crosara Teixeira M; Dos Santos Fernandes G
J Gastrointest Cancer; 2018 Sep; 49(3):227-236. PubMed ID: 29806062
[TBL] [Abstract][Full Text] [Related]
27. Opportunities for targeted therapies in hepatocellular carcinoma.
Thomas MB; Abbruzzese JL
J Clin Oncol; 2005 Nov; 23(31):8093-108. PubMed ID: 16258107
[TBL] [Abstract][Full Text] [Related]
28. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
29. Systemic therapy of advanced hepatocellular carcinoma.
Galle PR; Dufour JF; Peck-Radosavljevic M; Trojan J; Vogel A
Future Oncol; 2021 Apr; 17(10):1237-1251. PubMed ID: 33307782
[TBL] [Abstract][Full Text] [Related]
30. The role of molecular enrichment on future therapies in hepatocellular carcinoma.
Nault JC; Galle PR; Marquardt JU
J Hepatol; 2018 Jul; 69(1):237-247. PubMed ID: 29505843
[TBL] [Abstract][Full Text] [Related]
31. Multidisciplinary management of hepatocellular carcinoma: where are we today?
Marrero JA
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S3-10. PubMed ID: 23457037
[TBL] [Abstract][Full Text] [Related]
32. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hepatocellular carcinoma.
Giuliani F; Colucci G
Oncology; 2009; 77 Suppl 1():43-9. PubMed ID: 20130431
[TBL] [Abstract][Full Text] [Related]
34. Advanced HCC: emerging molecular therapies.
Finn RS
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):25-34. PubMed ID: 22419002
[TBL] [Abstract][Full Text] [Related]
35. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
[TBL] [Abstract][Full Text] [Related]
36. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular carcinoma.
Bergsland EK; Venook AP
Curr Opin Oncol; 2000 Jul; 12(4):357-61. PubMed ID: 10888422
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials.
Noonan A; Pawlik TM
Expert Opin Investig Drugs; 2019 Nov; 28(11):941-949. PubMed ID: 31590579
[No Abstract] [Full Text] [Related]
39. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
Zhu AX
Oncologist; 2006; 11(7):790-800. PubMed ID: 16880238
[TBL] [Abstract][Full Text] [Related]
40. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
